Synonyms: mPEG-PTH (1-34) | TransCon PTH | Yorvipath®
palopegteriparatide is an approved drug (EMA (2023), FDA (2024))
Compound class:
Peptide
Comment: Palopegteriparatide is a synthetic parathyroid hormone mimetic prodrug. Structurally it is an N-terminally PEGylated fragment of amino acids 1-34 of the mature human peptide (84 aa) [1]. Palopegteriparatide is inactive at the PTH receptor until the peptide-PEG linker is cleaved, releasing the active PTH(1-34) peptide.
|
Classification ![]() |
|
Compound class | Peptide |
Approved drug? | Yes. FDA (2024) | EMA (2023) |
International Nonproprietary Names ![]() |
|
INN number | INN |
11060 | palopegteriparatide |
Synonyms ![]() |
mPEG-PTH (1-34) | TransCon PTH | Yorvipath® |
Database Links ![]() |
|
CAS Registry No. | 2222514-07-8 (source: WHO INN record) |
GtoPdb PubChem SID | 500839894 |
Search PubMed clinical trials | palopegteriparatide |
Search PubMed titles | palopegteriparatide |
Search PubMed titles/abstracts | palopegteriparatide |